MedTrace Logo

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

NCT06345287 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2024-04-03

No results posted yet for this study

Summary

The aim of this study is to develop an adaptive radiation therapy plan for locally advanced head and neck squamous cell carcinoma receiving induction therapy containing immunotherapy and chemotherapy. The therapy plan is based on clinical remission, in order to reduce treatment-related toxic side effects without sacrificing clinical efficacy and improve the quality of life of patients.

Conditions

Interventions

RADIATION

radical radiotherapy (60Gy)

concurrent chemoradiotherapy (60Gy) after induction therapy

RADIATION

radical radiotherapy (66Gy)

concurrent chemoradiotherapy (66Gy) after induction therapy

RADIATION

radical radiotherapy (70Gy)

concurrent chemoradiotherapy (70Gy) after induction therapy

COMBINATION_PRODUCT

anti-PD-1 or PD-L1 antibody

immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Junlin Yi, Doctor · National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345287 on ClinicalTrials.gov